- Home
- WY vs RPRX Comparison
WY vs RPRX Comparison
Compare WY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WY
- RPRX
- Stock Information
- Founded
- WY 1900
- RPRX 1996
- Country
- WY United States
- RPRX United States
- Employees
- WY N/A
- RPRX N/A
- Industry
- WY Real Estate Investment Trusts
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- WY Real Estate
- RPRX Health Care
- Exchange
- WY Nasdaq
- RPRX Nasdaq
- Market Cap
- WY 18.0B
- RPRX 16.2B
- IPO Year
- WY N/A
- RPRX 2020
- Fundamental
- Price
- WY $22.75
- RPRX $38.74
- Analyst Decision
- WY Buy
- RPRX Strong Buy
- Analyst Count
- WY 8
- RPRX 3
- Target Price
- WY $31.00
- RPRX $46.00
- AVG Volume (30 Days)
- WY 6.0M
- RPRX 3.5M
- Earning Date
- WY 10-30-2025
- RPRX 11-05-2025
- Dividend Yield
- WY 3.70%
- RPRX 2.28%
- EPS Growth
- WY N/A
- RPRX N/A
- EPS
- WY 0.46
- RPRX 1.75
- Revenue
- WY $7,072,000,000.00
- RPRX $2,349,844,000.00
- Revenue This Year
- WY $0.04
- RPRX $36.16
- Revenue Next Year
- WY $3.97
- RPRX $2.04
- P/E Ratio
- WY $49.65
- RPRX $22.00
- Revenue Growth
- WY N/A
- RPRX 3.70
- 52 Week Low
- WY $22.29
- RPRX $24.05
- 52 Week High
- WY $32.70
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- WY 38.91
- RPRX 57.20
- Support Level
- WY $22.29
- RPRX $38.39
- Resistance Level
- WY $23.24
- RPRX $41.24
- Average True Range (ATR)
- WY 0.48
- RPRX 1.16
- MACD
- WY -0.02
- RPRX 0.21
- Stochastic Oscillator
- WY 29.12
- RPRX 50.33
About WY Weyerhaeuser Company
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.